Skip to Main Content

Why the Medicare Specialty Threshold Shouldn’t Drive Pricing Strategy

White Paper|

By Megan Thomas; Chad Gibson

Explores the considerations that a manufacturer should evaluate when estimating the impact of the specialty threshold in determining pharmaceutical pricing strategy. Also outlines why the specialty threshold should not be a key determinant in most pricing strategies.

Why the Medicare Specialty Threshold Shouldn’t Drive Pricing Strategy

Please submit the form below to view this resource.

Request Access

Please fill out the form below to access our Industry Resources.

By submitting this form, you agree to our use of this information for the purpose of contacting you. For more information, please refer to our privacy policy.

Maximize value across the product and patient journeys. Find out how.